

# Antonio Vitale

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9321506/antonio-vitale-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111  
papers

2,524  
citations

30  
h-index

43  
g-index

118  
ext. papers

3,041  
ext. citations

3.8  
avg, IF

4.7  
L-index

#	Paper	IF	Citations
111	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 899	5	2
110	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis.. <i>Ophthalmology and Therapy</i> , <b>2022</b> , 11, 887	5	1
109	Development and Implementation of the AIDA International Registry for Patients With Stillé Disease.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 878797	4.9	0
108	Impact of smoking habit on adult-onset Stillé disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , <b>2021</b> , 1	3.9	1
107	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. <i>Asia-Pacific Journal of Ophthalmology</i> , <b>2021</b> , 10, 360-365	3.5	4
106	Clinical profile and evolution of patients with juvenile-onset Behçeté syndrome over a 25-year period: insights from the AIDA network. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 2163-2171	3.7	1
105	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. <i>Rheumatology</i> , <b>2021</b> , 60, 5705-5712	3.9	1
104	The joint involvement in adult onset Stillé disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , <b>2021</b> , 11, 12455	4.9	3
103	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 668173	4.9	3
102	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211037178	3.8	0
101	Resolution of Schnitzleré syndrome after haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 704	2.2	
100	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 1936960	4.3	5
99	Long-Term Outcomes of Behçeté Syndrome-Related Uveitis: A Monocentric Italian Experience. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 6872402	4.3	5
98	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Stillé Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 42	4.9	6
97	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçeté syndrome. <i>Inflammopharmacology</i> , <b>2020</b> , 28, 711-718	5.1	7
96	Behçeté syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1031-1039	3.7	6
95	Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-βinhibition: a narrative review. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 327-337	3.9	7

94	Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8054961	4.3	8
93	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , <b>2020</b> , 2020, 8562485	4.3	13
92	Safety of systemic treatments for Behçet's syndrome. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 1269-1301	4.1	3
91	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , <b>2020</b> , 28, 298-304	2.8	26
90	Efficacy of monoclonal anti-tumour necrosis factor- $\alpha$ antibodies in uveitic macular oedema. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 621-625	2.2	
89	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 918	5.6	13
88	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 296	5.6	17
87	Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	41
86	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 407-415	3.9	34
85	Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1405-1411	2.4	26
84	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 1623847	4.3	16
83	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1468	5.6	7
82	Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 3293145	4.3	7
81	Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 58-63	2.8	23
80	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 34-39	2.8	25
79	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 63-70	3.9	22
78	Efficacy of anti-tumour necrosis factor- $\alpha$ monoclonal antibodies in patients with non-infectious anterior uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 301-305	2.2	7
77	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 680-683	2.2	19

76	Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 159-160	2.2	
75	Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1500-1507	9.5	36
74	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 1715-1720	3.9	12
73	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. <i>British Journal of Ophthalmology</i> , <b>2018</b> , 102, 637-641	5.5	30
72	Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behçet's disease. <i>Immunology Letters</i> , <b>2018</b> , 201, 38-44	4.1	17
71	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2805-2809	3.9	28
70	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2233-2240	3.9	52
69	Musculoskeletal manifestations in hereditary periodic fever syndromes. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 110, 25-31	2.2	
68	The eye involvement in monogenic autoinflammatory diseases: literature review and update. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 110, 44-53	2.2	4
67	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 517-521	0.9	3
66	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. <i>Israel Medical Association Journal</i> , <b>2018</b> , 20, 438-441	0.9	6
65	Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 110-115	2.2	7
64	Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2017</b> , 52, 34-44	12.3	9
63	A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 463-468	3.9	48
62	Canakinumab efficacy in refractory adult-onset PFAPA syndrome. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1050-1051	2.3	21
61	Challenges and new horizons in the periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 165-171	1.1	6
60	Certolizumab Pegol treatment in Behçet's disease with different organ involvement: A multicenter retrospective observational study. <i>Modern Rheumatology</i> , <b>2017</b> , 27, 1031-1035	3.3	27
59	The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 605-611	3.7	9

58	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet disease. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2063-2069	3.9	23
57	Quality of life impairment in Behçet disease and relationship with disease activity: a prospective study. <i>Internal and Emergency Medicine</i> , <b>2017</b> , 12, 947-955	3.7	31
56	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2017</b> , 33, 549-555	2.6	6
55	Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1687-1690	3.9	19
54	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 191-197	3.9	74
53	Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 1086-1088	1.6	10
52	Efficacy and safety of adalimumab in Behçet disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 183-189	3.9	59
51	Auditory involvement in Behçet disease: relationship with demographic, clinical, and therapeutic characteristics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 445-449	3.9	3
50	Adalimumab effectiveness in Behçet disease: short and long-term data from a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 451-455	3.9	45
49	Interleukin-1 blockade in neuro-Behçet disease: a case-based reflection. <i>International Journal of Rheumatic Diseases</i> , <b>2017</b> , 20, 1046-1049	2.3	6
48	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1018	8.4	17
47	Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 93-97	2.2	7
46	Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 104, 13-14	2.2	
45	Evolving Frontiers in the Treatment of Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Syndrome. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 444-447	0.9	11
44	Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. <i>Israel Medical Association Journal</i> , <b>2017</b> , 19, 478-483	0.9	15
43	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet disease: a multicenter retrospective study. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 1281-6	3.9	72
42	Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective PFAPA syndrome and Behçet disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 501-5	5.4	27
41		3.9	24

40	Lights and shadows in autoinflammatory syndromes from the childhood and adulthood perspective. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 565-72	3.9	6
39	Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 3	4.9	33
38	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 380	5.6	57
37	New therapeutic solutions for Behçet's syndrome. <i>Expert Opinion on Investigational Drugs</i> , <b>2016</b> , 25, 827-409	4.9	31
36	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. <i>Clinical Rheumatology</i> , <b>2016</b> , 35, 2631-2638	3.9	19
35	Anakinra long-term efficacy and safety in the management of Schnitzler's syndrome and latent tuberculosis infection. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 353	2.2	7
34	Interleukin-1 Inhibition in Behçet's disease. <i>Israel Medical Association Journal</i> , <b>2016</b> , 18, 171-6	0.9	22
33	One year in review 2016: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 357-72	2.2	17
32	Demographic, clinical and therapeutic findings in a monocentric cohort of adult patients with suspected PFAPA syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 77-81	2.2	19
31	Anakinra treatment in drug-resistant Behçet's disease: a case series. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1293-301	3.9	92
30	Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1817-20	3.9	20
29	Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). <i>Rheumatology International</i> , <b>2015</b> , 35, 1943-7	3.6	30
28	The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 17-28	3.9	36
27	Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 807-9	3.9	17
26	Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 473-5	2.3	5
25	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , <b>2015</b> , 9, 123	1.2	24
24	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 451675	4.3	17
23	Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 194864	4.3	64



22	One year in review 2015: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 259-71	2.2	27
21	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting with refractory chronic arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S171-2	2.2	6
20	Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. <i>Israel Medical Association Journal</i> , <b>2015</b> , 17, 93-7	0.9	17
19	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1220-9	13.6	69
18	Serum amyloid-A in Behçet's disease. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1165-7	3.9	13
17	Working the endless puzzle of hereditary autoinflammatory disorders. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 381-9	3.3	18
16	The hereditary autoinflammatory disorders uncovered. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 892-900	13.6	47
15	Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1197-207	3.9	49
14	Diagnosis and classification of relapsing polychondritis. <i>Journal of Autoimmunity</i> , <b>2014</b> , 48-49, 53-9	15.5	55
13	Untangling the web of systemic autoinflammatory diseases. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 948154	15.4	22
12	Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. <i>Dermatology</i> , <b>2014</b> , 228, 211-4	4.4	61
11	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 818-23	5.3	62
10	Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. <i>Mediators of Inflammation</i> , <b>2013</b> , 2013, 939847	4.3	60
9	Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. <i>International Journal of Rheumatology</i> , <b>2013</b> , 2013, 513782	2	63
8	The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 141-9	2.2	24
7	Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 155-6	2.2	30
6	Clinical and biochemical landmarks in systemic autoinflammatory diseases. <i>Annals of Medicine</i> , <b>2012</b> , 44, 664-73	1.5	32
5	The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. <i>Autoimmunity Reviews</i> , <b>2012</b> , 12, 10-3	13.6	38

4	Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. <i>Clinical Research in Cardiology</i> , <b>2012</b> , 101, 525-31	6.1	81
3	Diagnosis of PFAPA syndrome applied to a cohort of 17 adults with unexplained recurrent fevers. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 269-71	2.2	44
2	A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 593	2.2	36
1	Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 943-6	2.2	27